Before Indian drugmaker Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to ...

After disclosing a security breach last week concerning “a limited number of internal IT systems,” details on the cyber ...

Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for ...

With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since ...

With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line ...

As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business.  | ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

While describing the new import approval as a “tremendous step toward making prescription drugs affordable for all Coloradans ...

Recipharm has sketched out a “multi-million-dollar” investment in its U.S. manufacturing operations as part of a move to ...

In another Novo Nordisk manufacturing update, the company announced locally that it will invest 200 million yuan ($29 million ...

With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...

Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...